The Company deployed $6.1 million of capital expenditures in Q3 and remains on target with the Company’s guidance of approximately $20 million for the full year. AYR ended Q3 with aggregate cash, cash ...

“We significantly raised the profile of Alterity and ATH434 at the MDS Congress with several data presentations ... in efficacy endpoints to optimize design of a definitive Phase 3 study.

“We significantly raised the profile of Alterity and ATH434 at the MDS Congress with several data presentations ... in efficacy endpoints to optimize design of a definitive Phase 3 study.

Upcoming oral presentation for the ALLOHA TM Phase 1 heme trial at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition Company to host virtual ... treatment-arm patients and ...

After the company's remarks, we will conduct a question-and-answer ... Zaltenibart also continues to demonstrate a favorable safety profile with no observed safety signal of concern. The second PNH ...

Before we get started, let me remind you that our presentation and discussions will include ... facilities at lower rates and better availability, based on the company's improved credit profile. Paul ...

Michelin confused Dallas restaurant The Charles with the similar-sounding Mister Charles. A Recommended rating from Texas’ ...

Boeing is busily planning for future upgrades to the AH-64 Apache attack helicopter. While the scope of what is tentatively ...

Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call. At this time, all ...

Pharmacokinetic Results: TX45 demonstrated a potential best-in-class half-life for a long-acting relaxin therapy. Final analysis showed that a single dose of TX45 had approximately 50% subcutaneous ...

A2 Bio shares clinical study progress and the increased diversity of participants in the BASECAMP-1 prescreening study during the SITC annual meeting.